Combined spinal-epidural anesthesia for single and twin elective cesarean section
Conditions
Interventions
Group A-1:Ropivacaine dose 9.5 mg
Group A-2:Ropivacaine dose 11mg
Group A-3:Ropivacaine dose 12.5mg
Group A-4:Ropivacaine dose 14mg
Group A-5:Ropivacaine dose 15.5mg
Group B-1:Ropivacaine dose 9.5 mg
Group B-2:Ropivacaine dose 11mg
Group B-3:Ropivacaine dose 12.5mg
Group B-4:Ropivacaine dose 14mg
Group B-5:Ropivacaine dose 15.5mg
Sponsors
Women’s Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for single pregnancy in group A were: (1) ASA2; (2) puerpera aged 18 to 40; (3) body weight (=110 kg), height (= 150 cm); (4) gestational weeks (= 37 weeks); (5) Selective single cesarean section. Inclusion criteria for twin pregnancy in group B were: (1) ASA2; (2) puerpera aged 18 to 40; (3) body weight (=110 kg), height (=150 cm); (4) gestational weeks (=34 weeks); (5) Selective twin cesarean section.
Exclusion criteria
Exclusion criteria: Exclusion criteria for single pregnancy in group A were: (1) contraindication of intraspinal anesthesia; (2) allergy to amide local anesthetics; (3) pregnancy induced hypertension or preeclampsia; (4) gestational diabetes; (5) asthma and heart diseases requiring treatment; (6) refusal to sign informed consent; (7) other conditions: ruptured membranes, active labor, twins and multiple pregnancy caesarean section. Uterine delivery, intrauterine growth restriction, placenta previa, fetal congenital abnormalities, etc. Exclusion criteria for twin pregnancy in group B were: (1) contraindication of intraspinal anesthesia; (2) allergy to amide local anesthetics; (3) severe pregnancy-induced hypertension or preeclampsia; (4) uncontrolled severe gestational diabetes; (5) asthma and heart diseases requiring treatment; (6) refusal to sign informed consent; (7) other conditions: ruptured membranes, active delivery Cheng, single, triplets and above cesarean section, intrauterine growth restriction, placenta previa, fetal congenital abnormalities, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Successful rate of combined spinal-epidural anesthesia; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensory plane block;motor block;Pain score;General situation of pregnant women;Operation condition;Maternal vital signs;Umbilical Vein Blood Gas Analysis;Total placental weight;Total Birth Weight of Newborns;Neonatal Apgar Score;Adverse reactions such as hypotension; | — |
Countries
China
Contacts
Public ContactXiaowei Qian
Department of Anesthesia, Women’s Hospital, Zhejiang University School of Medicine
Outcome results
None listed